Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SalBenz-2
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
SalBenz-2 is an experimental **salicylanilide derivative** reported in preclinical medicinal chemistry research as an anticancer small molecule active against glioblastoma cells. In the cited study, SalBenz-2 was part of a series of substituted salicylanilides and related benzoate derivatives evaluated in U87 human glioblastoma models, where it reduced cell viability and was associated with induction of autophagy, as reflected by light chain 3 processing. The compound appears to be a research-stage chemical entity rather than a clinically developed pharmaceutical product, and no specific developer, manufacturer, approved indication, or validated molecular target was clearly established from the provided source.
- Other names
- SalBenz-2SalBenz2SalBenz 2
Beyond the preview
Go deeper on SalBenz-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SalBenz-2.